AGLE - Aeglea inks deal with Immedica for Europe Middle East rights to rare disease therapy

Aeglea BioTherapeutics (AGLE) has signed an agreement with Immedica Pharma AB giving the latter commercialization rights to pegzilarginase for the treatment of Arginase 1 Deficiency in Europe and the Middle East.Under the terms of the agreement, Immedica will make an upfront payment of $21.5 million to Aeglea.Aeglea is also eligible to receive up $130M in regulatory and commercial milestones, and mid-twenties percentage royalties on sales.Pegzilarginase is currently in phase 3 development with top-line data expected in Q4 2021.ARG1-D is a rare disease seen in early childhood with patients experience spasticity, seizures, developmental delay, intellectual disability, and early mortality.Aeglea shares are up 0.6% to $7.93 in morning trading.

For further details see:

Aeglea inks deal with Immedica for Europe, Middle East rights to rare disease therapy